Hyaluronan-based Drug-Delivery Vehicle Development Service

CD BioGlyco has a highly trained development team to assist clients with Marine Carbohydrate-based Drug-Delivery Vehicle Development services. Hyaluronan (HA) is a negatively charged linear heteropolysaccharide composed of N-acetylated hexosamine and glucuronic acid. Its primary binding receptor is the single-gene encoded transmembrane protein cluster of differentiation 44 (CD44).

HA-based Drug-Delivery Vehicle Development Service at CD BioGlyco

Targeting HA-based Drug-delivery Vehicle Synthesis and Characterization Service

Our researchers use the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC)/N-hydroxy succinimide (NHS) method to attach HA to the surface of the vehicle (nanoparticles). Furthermore, we provide characterization services by static and dynamic light scattering (SLS and DLS), transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FT-IR), and nuclear magnetic resonance (NMR).

Drug Loading Service

We obtain drug-loaded vehicles by rapid nanoprecipitation. The drug solution is mixed and incubated in an organic solvent with the vehicle. The unencapsulated drug is removed from the precipitation medium by dialysis and insoluble drug aggregates are removed using cellulose filters. The quantification of the drug is done based on the calibration curve generated from the assay in 96 well plates.

Bioactivity Analysis Service

Fig.1 Schematic illustration of HA-based drug-delivery vehicle synthesis and analysis. (CD BioGlyco)

Publication

Technology: FT-IR, NMR, Confocal microscopic imaging, Flow cytometric analysis

Journal: ChemistryOpen

Published: 2021

Results: In this paper, platinum nanoclusters (Pt NCs) were used as the basis for surface modification of HA to synthesize multifunctional HA-Pt NCs-NH₂. Three types of non-small cell lung cancer cell (NSCLC) cells H1299, small cell lung cancer (SCLC) cells H446, and normal HFL1 lung fibroblasts, were selected as targets. The distribution of HA-Pt NCs-NH₂ was examined and found that HA-Pt NCs-NH₂ showed a superior selective targeting binding to SCLC H446 cells. HA-Pt NCs-NH₂ significantly inhibited the growth and invasive activity of H1299 cells and significantly induced apoptosis in NSCLC cells. In conclusion, HA-Pt NCs-NH₂-based chemotherapeutic agents were accurately targeted for diagnosing and treating NSCLC.

Fig.2 Expression mapping of H1299 cell migration and invasion. (Liu, et al., 2021)

Applications

• The HA-based drug-delivery vehicle is an effective cancer therapeutic tool with strong anti-proliferative activity against CD44 overexpressing cancer cells, including human breast, colon, ovarian, gastric, breast, esophageal, and lung cancers.
• HA-based drug-delivery vehicles can be used for simultaneous tumor photodynamic imaging and treatment studies.
• HA-based drug-delivery vehicle can be used as a fluorescent marker for selective fluorescence imaging of hematological K562 and BV173 tumor cells.
• HA-based drug-delivery vehicle inhibits the proliferation of hematopoietic malignant cells through the pro-apoptotic proteins p53 and caspases, which has great potential in the diagnosis and treatment of hematological diseases.

Advantages of Us

• Our drug-delivery vehicle development services overcome the difficulties of therapeutic delivery, especially precise anchoring to the release site.
• We provide a very comprehensive analytical and characterization service. All the data is processed by a professional and sent to your mailbox.

CD BioGlyco releases the drug-delivery vehicle at specific locations through either active or passive targeting mechanisms. We offer comprehensive Marine Biomolecule production services. Our researchers have extensive experience in the field of marine polysaccharides. Please feel free to contact us.